Almac Group Awarded with Six CDMO Leadership Awards Across all Core Categories
February 21, 2023
Overall recognition received for compatibility, expertise, quality and reliability.
Craigavon, N.I. – Almac Group, the global contract development and manufacturing organisation, is delighted to announce it has won six CDMO Leadership Awards for 2023.
The CDMO Leadership Awards recognise top performing CDMOs, celebrating outstanding companies in drug development and manufacturing, emphasising high standards of quality, integrity and innovation exemplified in their work. The winners will be presented with an award at a ceremony on 22nd March in New York.
Primary market research by Industry Standard Research (ISR) is the basis of the awards. 72 contract manufacturers were assessed by 23 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey. This experiential feedback was analysed by sponsor company size to reveal leading CDMOs in different performance categories. CDMOs must meet the minimum threshold of customer survey responses to be eligible for an award.
Almac was successful in achieving awards in all core categories including:
- Excellence in Capabilities (Small Pharma)
- Compatibility (Overall and Small Pharma)
- Expertise (Overall and Small Pharma)
- Quality (Overall and Small Pharma)
- Reliability (Overall and Small Pharma)
- Service (Small Pharma)
Winners in each of these categories were judged by their customers as either exceeding expectations or as top performers in outsourced projects conducted within the past 18 months.
Outside of the core metrics, Almac also received individual attribute awards for five additional categories – accessible senior management, innovation, on-time delivery, reputation and right first time.
John McQuaid, President and Managing Director, Almac Pharma Services, commented: “I am both delighted and proud that Almac has been recognised again by Life Science Leader at the annual CDMO awards. To have won in all six categories, and four overall reflects the commitment of the Almac team who work hard to provide best-in-class, tailored solutions to our global client base and their patients. The accreditations are particularly meaningful as we have been evaluated by customers we have partnered with.”
Stephen Barr, President and Managing Director, Almac Sciences, added: “To receive this recognition, influenced directly from our clients, is a fantastic endorsement and testament to our excellence in research, development and manufacturing of high-quality chemical products used in high-profile consumer industries across the globe. We are delighted that Life Science Leader has recognised our team for delivering innovative, original, and high-quality service and solutions in these categories which has contributed significantly to the betterment of human health.”
Kate Hammeke, Vice President, Industry Standard Research said “Industry Standard Research is proud to be a part of the CDMO Leadership Awards. ISR’s research methodology ensures that the people who participate in the contract manufacturing benchmarking market research are highly qualified decision-makers with first-hand experience working with the suppliers they evaluate. These awards are based on experiential feedback and enable users of ISR’s market research to make data-driven decisions with respect to choosing an outsourcing partner. It also means the winners of these awards have been delivering the highest quality of service according to their current and recent customers and are deserving of these accolades for their distinction.”
To learn more about Almac’s exceptional culture and commitment to quality, please visit our website: https://www.almacgroup.com
About Almac Pharma Services
Tailormade pharmaceutical development and commercial solutions
With over 50 years’ experience, Almac Pharma Services is a world leading outsourcing partner to the global pharmaceutical and biotechnology industry.
Employing over 1,600 highly skilled individuals across 4 locations in Europe and the US, the company provides tailored, quality-led and timely solutions from early and late phase pharmaceutical development, clinical and commercial drug product manufacture, product launch through to commercial packaging and global distribution.
About Almac Sciences
Think Almac for API development & manufacturing solutions
With 900 highly skilled employees, spanning across 4 locations globally, Almac Sciences provides services for all stages of drug development for small molecules and peptides. Our expertise includes: API supply (pre-clinical to commercial manufacture); drug product development; stable and 14C radiolabelling; solid state services and, biocatalysis, all of which are fully supported by a dedicated Analytical team.
About Almac Group
A unique culture delivering exceptional solutions.
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation which has grown organically over the past five decades now employing over 6,600 highly skilled personnel across 18 facilities including Europe, the US and Asia.
To keep up to date with latest news, follow us on Twitter and LinkedIn or visit almacgroup.com.